Abstract

We previously reported that chronic nicotine infusion blocks development of Pneumocystis pneumonia. This discovery developed from our work demonstrating the inability of this fungal pathogen to synthesize the critical metabolic intermediate S-adenosylmethionine and work by others showing nicotine to cause lung-specific reduction of S-adenosylmethionine in guinea pigs. We had found nicotine infusion to cause increased lung ornithine decarboxylase activity (rate-controlling enzyme of polyamine synthesis) and hypothesized that S-adenosylmethionine reduction is driven by up-regulated polyamine biosynthesis. Here we report a critical test of our hypothesis; inhibition of ornithine decarboxylase blocks the effect of nicotine on lung S-adenosylmethionine. Further support is provided by metabolite analyses showing nicotine to cause a strong diversion of S-adenosylmethionine toward polyamine synthesis and away from methylation reactions; these shifts are reversed by inhibition of ornithine decarboxylase. Because the nicotine effect on Pneumocystis is so striking, we considered the possibility of tissue specificity. Using laser capture microdissection, we collected samples of lung alveolar regions (site of infection) and respiratory epithelium for controls. We found nicotine to cause increased ornithine decarboxylase protein in alveolar regions but not airway epithelium; we conclude that tissue specificity likely contributes to the effect of nicotine on Pneumocystis pneumonia. Earlier we reported that the full effect of nicotine requires 3 weeks of treatment, and here we show recovery is symmetrical, also requiring 3 weeks after treatment cessation. Because this time frame is similar to pneumocyte turnover time, the shift in polyamine metabolism may occur as new pneumocytes are produced.

Highlights

  • A critical test of the hypothesis that nicotine causes lung AdoMet depletion by stimulating polyamine metabolism was to determine whether blocking polyamine synthesis would block nicotine-induced AdoMet depletion

  • One approach would be to inhibit the AdoMet-consuming step of polyamine metabolism, decarboxylation of AdoMet by AdoMetDC

  • In contrast to inhibitors of AdoMetDC, DFMO is extraordinarily specific and has no other metabolic effects. This specificity is due to DFMO being an enzyme-activated suicide inhibitor that is metabolically inert until the carboxyl group is cleaved by ornithine decarboxylase (ODC)

Read more

Summary

EXPERIMENTAL PROCEDURES

Chemicals and Supplies—DFMO was from ILEX Oncology, (San Antonio, TX). Ultrapure AdoMet, spermidine, spermine, putrescine and R-(ϩ)-nicotine were from Sigma-Aldrich. After trimethoprim and sulfamethoxazole treatment, infusion pumps were implanted and delivered saline during the 7 days allowed for recovery before immunosuppression was begun by adding dexamethasone in the drinking water (1.5 mg lϪ1), and drug delivery was begun by changing pump solutions. This protocol was used because earlier nicotine lung AdoMet data were collected with immunosuppressed rats. Analysis for AdoMet, AdoMet Metabolites, and Polyamines— The AdoMet contents of lung, liver, and plasma samples were measured by HPLC analysis using Waters AccQ.Fluor derivitizing reagent as previously reported [1].

RESULTS
45 Ϯ 21 844 Ϯ 72c
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call